- Qiagen reported second-quarter 2014 net income of $32.8 million, or $0.14 per diluted share.
- Adjusted net sales came in at $331.2 million, up 4% at constant exchange rates or CER.
- In my original article I said that despite being able to grow revenue, Qiagen failed to convert that incremental revenue to profit over the last five years.
- The trend continues this quarter also, as the company’s EPS is still hovering around the five-year trend line.
- The company’s recently announced joint venture with AstraZeneca might be a positive development for investors.
Qiagen's (NASDAQ:QGEN) second-quarter 2014 adjusted EPS came in at 14 cents, a huge improvement from the year-ago loss of 22 cents, and adjusted net sales came in at $331.2 million, up 4% at CER. However, investors should note that the second-quarter 2013 loss was an unusual event and the year-over-year improvement is absolutely insignificant. The fact of the matter is that Qiagen's EPS is still hovering around the five-year trend line. In my original article, I said that unless there is a noticeable reversal in this trend, I wouldn't recommend buying the stock, and I continue to hold my opinion after the second-quarter earnings.
QGEN EPS Diluted (Quarterly) data by YCharts
Qiagen's H1 2014 adjusted net sales rose approximately 8% at CER excluding U.S. HPV tests, which as I noted in my original article, has been slowing with a contracting U.S. HPV market with lower ASP. Qiagen's CEO Peer M. Schatz said, "Qiagen achieved solid increases in adjusted net sales and earnings in the second quarter of 2014 while moving ahead to accelerate innovation and growth. We are reaffirming full-year expectations set after having delivered on our targets for the first half of 2014." However, I'm not prepared to buy the claim of Qiagen's CEO in the absence of visible earnings growth.
However, a few days ago Qiagen signed up a deal with AstraZeneca (NYSE:AZN) to develop a diagnostic test using simple blood samples to identify patients who will benefit from AstraZeneca's lung cancer pill Iressa, which will be built on Qiagen's FDA-approved therascreen EGFR test and is planned to run on Rotor-Gene Q, member of the QIAsymphony family of automated instruments. I feel the deal could be slightly positive from investors' point of view, since Qiagen's QIAsymphony revenue could increase as a result of the deal. However, I would like to see the incremental revenue is converted into profit before recommending investing in the company. For more insight, read my original analysis.